MYNZ — Mainz Biomed NV Income Statement
0.000.00%
Last trade - 00:00- $10.04m
- $10.09m
- $0.89m
Annual income statement for Mainz Biomed NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.494 | 0.577 | 0.53 | 0.895 | 0.894 |
| Cost of Revenue | |||||
| Gross Profit | 0.123 | 0.178 | 0.182 | 0.51 | 0.575 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.16 | 12.3 | 26.9 | 27.5 | 19.6 |
| Operating Profit | -0.665 | -11.7 | -26.4 | -26.6 | -18.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.587 | -11.7 | -26.4 | -26.3 | -21.7 |
| Net Income After Taxes | -0.587 | -11.7 | -26.4 | -26.3 | -21.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.587 | -11.7 | -26.4 | -26.3 | -21.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.587 | -11.7 | -26.4 | -26.3 | -21.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.76 | -27.7 | -74.8 | -64.9 | -22.1 |
| Dividends per Share |